Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).
The present disclosure relates to implantable cardiac devices and methods of operating cardiac devices. The invention is set out in the appended claims.

US2008/0119902A1 describes methods and systems for classifying cardiac responses to pacing stimulation and managing retrograde conduction and pacemaker mediated tachyarrhythmia. An atrial pacing pulse and a ventricular pacing pulse are delivered during a paced cardiac cycle. A post ventricular atrial refractory period (PVARP) is timed following the ventricular pacing pulse. The system determines if the atrial pacing pulse captures the atrium. An atrial depolarization occurring after the paced cardiac cycle is sensed. Retrograde management is initiated if the atrial pacing pulse did not capture the atrium and the atrial depolarization occurred during the PVARP. Pacemaker mediated tachyarrhythmia (PMT) is initiated if the atrial pacing pulse did not capture the atrium and the atrial depolarization did not occur during the PVARP.

EP1118351A2 describes a system and method for performing autocapture/autothreshold detection in an implantable cardiac stimulation device or any device capable of stimulating some organ or tissue in the body. The determination of whether there is a loss-of-capture is determined only according to paced events, i.e., ignoring intrinsic and PVC beats. Furthermore, the loss-of-capture determination is based upon X out of the last Y beats, where Y is greater than 2 and X is less than Y. Accordingly, consecutive loss-of-capture events are no longer required in determining the threshold level. One embodiment monitors cardiac events to detect a sequence of patterns that could indicate a trigeminy pattern and, if detected, the pacing rate is increased to attempt to break the pattern and thus permit the threshold level to be detected.

US 2003/0208241 describes techniques for providing capture verification during over-device pacing.

Some of the embodiments described in this disclosure relate to methods used for capture threshold testing. According to some methods, cardiac cycles are detected and cardiac events of a cardiac chamber that occur during the cardiac cycles are monitored. The number of intrinsic beats in the cardiac events is counted. The pacing rate for a capture threshold test is initialized. A pre-test pacing rate is maintained for the capture threshold test if the number of intrinsic beats in the cardiac events is less than a threshold. The pacing rate is increased for the capture threshold test if the number of intrinsic beats in the cardiac events is greater than the threshold. The capture threshold test is performed using the initialized pacing rate.

In some implementations, if the pre-test rate is greater than a maximum rate, the rate initialization process is terminated.

Monitoring the cardiac events may include monitoring the cardiac events that occur during the cardiac cycles until a predetermined number of cardiac events have occurred.

Some implementations further include counting a number of consecutive atrial events that are intrinsic beats or fusion beats to determine an intrinsic/fusion beat count.

According to some aspects, after initializing the atrial pacing rate, the pacing rate during the capture threshold test is set by maintaining a previous pacing rate if the intrinsic/fusion beat count is less than a predetermined value; and increasing the previous pacing rate if the intrinsic/fusion beat count is greater than the predetermined value. Detecting cardiac cycles may be performed by detecting certain end events that signify the end of a cardiac cycle.

In some cases, the cardiac events are atrial events, the intrinsic beats are atrial intrinsic, and the pacing rate is an atrial pacing rate.

In some cases, the cardiac events are ventricular events, the intrinsic beats are ventricular intrinsic beats, and the pacing rate is a ventricular pacing rate.

Some embodiments discussed in this disclosure involve cardiac pacing devices. The device includes sensing circuitry configured to detect cardiac signals that include indications of cardiac events. A control processor is configured to monitor the cardiac events that occur during cardiac cycles and to count a number intrinsic beats in the cardiac events. The control processor includes circuitry configured to initialize a pacing rate for a capture threshold test (CTT). The control processor is configured to maintain a pre-test pacing rate during the capture threshold test if the number of intrinsic beats in the cardiac events is less than a threshold and to increase the pre-test pacing rate during the capture threshold test if the number of intrinsic beats in the cardiac events is greater than the threshold. The cardiac device includes pacing circuitry configured to deliver pacing during the capture threshold test using the initialized pacing rate.

In some cases, the control processor is configured to determine if the pre-test rate is greater than a maximum rate and to end the initialization if the pre-test rate is greater than the maximum rate.

According to some implementations, the control processor is configured to monitor the cardiac events that
occur during the cardiac cycles until a number of cardiac events have occurred.

[0015] The control processor may be configured to count a number of consecutive cardiac events that are intrinsic beats or fusion beats to determine an intrinsic/fusion beat count. The previous pacing rate may be maintained if the intrinsic/fusion beat count is less than a predetermined value and the previous pacing rate may be increased if the intrinsic/fusion beat count is greater than the predetermined value.

[0016] In some cases, the cardiac events are atrial events, the intrinsic beats are atrial intrinsic beats, and the pacing rate is an atrial pacing rate.

[0017] In some cases, the cardiac events are ventricular events, the intrinsic beats are ventricular intrinsic beats, and the pacing rate is a ventricular pacing rate.

[0018] Some embodiments include a control processor configured to control the performance of a capture threshold test (CTT), the control processor is configured to count, during the CTT, a number of consecutive cardiac events that are intrinsic beats or fusion beats to determine an intrinsic/fusion beat count, the control processor further configured to maintain a previous pacing rate during the CTT if the intrinsic/fusion beat count is less than a predetermined value and to increase the previous pacing rate during the CTT if the intrinsic/fusion beat count is greater than the predetermined value.

[0019] The control processor may be configured to terminate the test if the paced cardiac rate is greater than a predetermined rate. The control processor may terminate the capture threshold test if a predetermined number of rate increases have occurred. The invention is set out in the appended claims. The aspects, examples, implementations or embodiments according to the present description that do not fall within the scope of the claims are provided for illustrative purposes only.

[0020] Advantages and attainments, together with a more complete understanding will become apparent and appreciated by referring to the following detailed description and claims in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 is a flow diagram that illustrates a method of operating a cardiac device to initialize a pacing rate for atrial capture threshold testing in accordance with embodiments described herein;

Figures 2A and 2B provide a flow diagram of a method of operating a cardiac device to initialize the atrial pacing rate prior to atrial capture threshold testing;

Figure 3 is a flow diagram illustrating a method for atrial intrinsic/fusion beat management that may be implemented during an atrial capture threshold test;

Figures 4A and 4B shows a more detailed flow diagram for intrinsic/fusion beat management which may be implemented during an atrial capture threshold test to reduce the likelihood of occurrence of intrinsic or fusion beats during the atrial capture threshold test;

Figure 5 illustrates a process for performing an atrial pacing rate increase after a rate increase has been requested during rate initialization prior to an atrial capture threshold test or during the atrial capture threshold test;

Figure 6 illustrates an implantable cardiac rhythm management (CRM) system that may be used in connection with pacing methods in accordance with embodiments described herein;

Figure 7 is a block diagram of the circuitry of the implantable cardiac device according to embodiments described herein;

Figure 8 is a flowchart illustrating a method for classifying the cardiac response to pacing that may be implemented by a CRM device in accordance with embodiments described herein;

Figure 9A is a graph illustrating the morphology of a cardiac signal sensed following an atrial pace;

Figure 9B is a diagram illustrating regions within the peak timing interval used in pacing response discrimination in accordance with embodiments described herein;

Figure 10 is a flowchart illustrating step down capture threshold testing with pacing response classification based on the regions depicted in Figure 9B in accordance with embodiments described herein;

Figure 11 is a diagram illustrating regions used in pacing response discrimination in accordance with embodiments described herein;

Figures 12A-12B illustrate a flowchart illustrating step down capture threshold testing with pacing response classification based on the regions depicted in Figure 11 in accordance with embodiments described herein;

Figure 13 is a flowchart that illustrates an approach implementable in a CRM system for retrograde conduction management and PMT management in accordance with embodiments described herein;

Figure 14 is a timing diagram illustrating a scenario where loss of capture may be erroneously detected due to retrograde conduction;

Figure 15 is a timing diagram illustrating retrograde management in accordance with embodiments described herein;
After delivery of a pacing pulse to a heart chamber, various cardiac responses to the pacing pulse are possible. In one scenario, the pacing pulse may generate a propagating wavefront of depolarization resulting in a contraction of the heart chamber. In this scenario, the pacing pulse is said to have captured the heart chamber. Capture of the heart chamber may occur if the pacing pulse has sufficient energy and is delivered during a non-refractory period. If the pacing pulse does not produce contraction of the chamber, the cardiac response is referred to as non-capture or loss of capture. Non-capture may occur, for example, if the pacing pulse energy is too low, and/or if the pacing pulse is delivered during a refractory period of the cardiac tissue. Fusion occurs when a depolarization initiated by a pace merges with an intrinsic depolarization.

Capture threshold determination is distinguishable from automatic capture detection, a procedure that typically occurs during therapeutic pacing, rather than during test mode pacing. Automatic capture detection verifies that a delivered pace pulse results in a captured response. When a captured response is not detected following a pace pulse, the pacemaker may deliver a back up safety pace to ensure consistent pacing. If back up pacing is implemented, the back up pace may be delivered, for example, about 70-80 ms after the initial pace pulse. If a predetermined number of pace pulses delivered during normal pacing do not produce a captured response, the pacemaker may initiate a CTT to determine the capture threshold. Alternatively, if a predetermined number of pacing pulses do not produce a captured response, the pacemaker may adjust the pacing energy for the next pacing pulse.

Figure 1 is a flow diagram that illustrates a method 100 of operating a cardiac device to initialize a pacing rate for an atrial CTT in accordance with embodiments described herein. The method 100 determines if the current pacing
rate is at a rate high enough to avoid fusion during the atrial CTT. Prior to the commencement of the atrial CTT, the cardiac device monitors 110 atrial events that occur during a predetermined number of cardiac cycles. The atrial events may be paced atrial beats, intrinsic atrial beats, and/or fusion atrial beats, for example. In some cases, the device looks for a minimum number of the atrial events, e.g., about ten atrial events that occur during about fifteen cardiac cycles. If the minimum of atrial events is not detected during the cardiac cycles, then the atrial CTT may be terminated. Optionally, a failure code indicating the reason for the failure of the atrial CTT may be generated.

[0031] The number of the atrial events that are intrinsic atrial beats are counted 130. The device compares 140 the number of intrinsic atrial beats that occur during monitoring the atrial events to a threshold. In some implementations, the threshold is about six, so if the number of sensed intrinsic atrial beats is greater than or equal to six intrinsic beats in about ten atrial events, there is sufficient intrinsic atrial activity to indicate that fusion is likely to occur during the atrial CTT. The cardiac device increases 150 the pacing rate to avoid fusion. For example, the device may increase the pacing rate by about ten beats per minute. If the number of sensed intrinsic atrial beats that occur during monitoring 110 the atrial events is less than the threshold, it is likely that the pacing rate is adequate to avoid fusion. The cardiac device maintains 160 the current pacing rate.

[0032] Figures 2A and 2B illustrate a more detailed flow diagram of a method of operating a cardiac device to initialize the atrial pacing rate prior to an atrial CTT. The device counts the number of consecutive cardiac cycles, counts the number of atrial events that occur during the consecutive cardiac cycles, and counts the number atrial events that are fusion or intrinsic events beats.

[0033] The device monitors cardiac cycles which are terminated by cardiac cycle end events. Cardiac cycle end events for various pacing modes are provided in Table 1.

<table>
<thead>
<tr>
<th>Cardiac Cycle End Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>DDI(R) or DDD(R) (LV only)</td>
</tr>
<tr>
<td>RV sense</td>
</tr>
<tr>
<td>LV pace</td>
</tr>
<tr>
<td>LV pace noise inhibited</td>
</tr>
<tr>
<td>LV pace LVPP inhibited</td>
</tr>
<tr>
<td>DDI(R) or DDD(R) (Bi-V or RV only)</td>
</tr>
<tr>
<td>RV sense</td>
</tr>
<tr>
<td>RV pace</td>
</tr>
<tr>
<td>RV pace noise inhibited</td>
</tr>
<tr>
<td>LV pace LVPP inhibited</td>
</tr>
<tr>
<td>AAI(R)</td>
</tr>
<tr>
<td>A sense (non-refractory)</td>
</tr>
<tr>
<td>A pace</td>
</tr>
<tr>
<td>A pace noise inhibited</td>
</tr>
</tbody>
</table>

[0034] Where LV/RV/A pace noise inhibited is a pace that is scheduled, but inhibited due to the noise response of the device; LV pace LVPP inhibited is a pace that is inhibited if it would occur within a predetermined interval following a left ventricular depolarization. If a cardiac end event occurs 210, a consecutive cycle counter is incremented 220. The device compares 230 the number of consecutive cardiac cycles to a cycle count threshold. The cycle count threshold may be about 15 or 20, for example. If the number of consecutive cardiac cycles is greater than the cycle threshold without detecting enough atrial events, rate initialization for the atrial CTT may be terminated and/or retried 235. If, however, the number of consecutive cardiac cycles is less than the cycle count threshold, the method checks 240 to determine if the cardiac event was a non-refractory atrial event, i.e., an atrial fusion beat, non-refractory intrinsic atrial beat, or an atrial pace. Refractory atrial sensed beats are not included in the rate initialization process in this example.

[0035] If the cardiac event is not 240 an atrial event, the process waits 265 for the next event. If the cardiac event is 240 an atrial event, the atrial event counter is incremented 245. If the cardiac event is an atrial event and the atrial event is 250 an intrinsic atrial beat, the atrial intrinsic beat counter is incremented 255. If the atrial event is not an atrial intrinsic beat then the process waits 265 for the next event.

[0036] The device checks 260 to determine if the number of atrial events is greater than or equal to the atrial event threshold. The atrial event threshold may be about ten atrial events, for example. If the device determines 260 that the number of atrial events is less than the atrial event threshold, there are not enough atrial events to assess and the device waits 265 for another atrial event. The method continues to loop until the number of cardiac cycles exceeds the cycle threshold or the number of atrial events is greater than or equal 260 to the atrial event threshold. If the number of atrial events is equal to or greater than 260 the atrial event threshold, then a sufficient number of atrial events have occurred and the rate initialization process continues (see Figure 2B).

[0037] The device determines the pre-test cardiac rate (or cardiac cycle interval) and checks to determine if the pacing rate can be increased for the CTT. If the pre-test cardiac rate is 270 above a maximum rate, e.g., about 110 beats per minute, then the atrial CTT is terminated and/or retried 275 at a later time. If, however, the pre-test cardiac rate is below or equal to 270 the maximum cardiac rate, the device proceeds with comparing 280 the number of counted atrial intrinsic beats (counted by the atrial intrinsic beat counter) to the atrial intrinsic beat threshold. In some cases, the atrial intrinsic
beats that are either intrinsic atrial beats or fusion beats. The I/F counter is reset if an atrial pace occurs. If more than a predefined number of atrial intrinsic or fusion beats (e.g., 5 atrial intrinsic or fusion beats of which at least 2 are atrial intrinsic beats) occur at any time after rate initialization, the device will perform a rate increase. Each rate increase increases the pacing rate by about 10 beats per minute (bpm) with a maximum number of rate increases in any CTT, e.g., about 2 rate increases, and a pacing rate upper limit, e.g., about 110 bpm. Rate increases may be applied to the filtered average rate rather than the lower rate limit (LRL), i.e., the rate is increased 10 beats per minute (bpm) above the current average rather than 10 bpm above the last pacing rate or the LRL.

Figure 3 is a flow diagram illustrating a method for atrial intrinsic/fusion beat management that may be implemented during an atrial CTT. During the CTT, atrial cardiac events are monitored. For example, the monitored atrial events can include intrinsic atrial beats, paced atrial beats, and atrial fusion beats. The device counts the number of consecutive intrinsic atrial beats or atrial fusion beats. The intrinsic atrial beats are intrinsic beats that occur before an atrial pacing pulse is delivered for the cardiac cycle and these intrinsic beats may inhibit delivery of the scheduled pacing pulse. The device resets the counter when a paced atrial beat occurs. If the number of consecutive intrinsic atrial beats or atrial fusion beats is greater than an intrinsic/fusion threshold (I/F threshold), with a minimum number of intrinsic beats, the pacing rate is increased. If the number of consecutive intrinsic beats or fusion beats does not reach the I/F threshold, the current pacing rate is maintained.

Figure 4 shows a more detailed flow diagram for intrinsic/fusion beat management which may be implemented during an atrial CTT to reduce the likelihood of occurrence of intrinsic or fusion beats during the CTT. After the occurrence of a cardiac event, the device determines if the cardiac event is an event that ends a cardiac cycle. Cardiac cycle end events for various pacing modes are provided in Table 1. If the cardiac event is a cardiac cycle end event, the device updates the cardiac cycle time using the interval ended by the cardiac cycle end event. The cardiac cycle time is determined as a weighted average of cardiac cycle intervals. It will be appreciated that the cardiac rate is the inverse of the cardiac cycle time and that either parameter may be used as an indication of the rate of occurrence of cardiac events. In one implementation, the weighted average used to update the cardiac cycle time (CT) is calculated as Equation 1.

\[
CT = A1 \times \text{current value of } CT + A2 \times \text{previous value of } CT
\]  

[1]

where A1 and A2 can be any appropriate coefficients, e.g., A1 = 0.25 and A2 = 0.75.

The device may be smoothed using an infinite impulse response (IIR) filter implementing Equation 1 to lessen the effects of spurious fast beats.

The device determines whether or not the present cardiac rate is greater than a maximum cardiac rate. The maximum cardiac rate may be about 110 bpm, for example. If the present cardiac rate is greater than the maximum rate, the device checks if the event is an atrial event 420 (Figure 4B). If the present cardiac rate is greater than 410 a maximum cardiac rate, a consecutive high rate cycle counter (CHR counter) is incremented and a total high rate cycle counter (THR counter) is incremented. The CHR counter counts the number of consecutive beats that have a CT greater than the maximum rate. The THR counter counts the total number of beats (consecutive or non-consecutive) that have a CT greater than the maximum rate. If the CHR counter exceeds a maximum number (maxCHR) or if the THR counter exceeds a maximum number (maxTHR), then the threshold test terminates and may be attempted at a later time.

If neither CHR nor THR counters have reached their respective terminal counts, the device determines 420 (Figure 4B) that the event is an atrial event. The device checks 422 if the atrial event is an atrial pace or a noise inhibited atrial pace. If the atrial event is not 422 an atrial pace or a noise inhibited atrial pace, the device determines 426 whether or not the atrial event is an atrial refractory sensed event, i.e., an atrial event sensed during a refractory period, such as the post ventricular atrial refractory period (PVARP). If the atrial event is 426 a refractory sensed event, the next scheduled atrial pace occurs after the atrial tissue recovers.
and is no longer refractory following the refractory sensed event. For example, the next scheduled atrial pace may be delayed so that the next pace occurs at least about 300 ms after the sensed refractory atrial event.

If the atrial event is not 426, 428 a non-refractory intrinsic event, then the I/F counter is incremented 430. The I/F counter counts non-refractory intrinsic atrial beats and atrial fusion beats. If the atrial event is a non-refractory intrinsic event, then the atrial intrinsic event (AIE) counter is incremented. The I/F counter is checked 432 to determine if the I/F counter value is greater than an I/F threshold and the AIE counter is checked to determine if the AIE counter is greater than the AIE threshold. In some cases, the I/F threshold may be about 5 and the AIE threshold may be about 2. If the I/F count does not exceed 432 the I/F threshold or the AIE counter does not exceed the AIE threshold, then the process loops to look for the next cardiac event. If the number of intrinsic atrial beats and fusion beats counted by the I/F counter exceeds 432 the I/F threshold and the number of AIE beats exceeds the AIE threshold, then a rate increase is requested 434.

At step 422, if the atrial event is a delivered atrial pace or an atrial pace that was inhibited by noise, the device determines 424 whether or not the paced atrial rate is greater than a maximum atrial pacing rate. For example, the atrial pacing rate corresponding to the interval between atrial paces (Ap-Ap) or the interval between an atrial pace and a noise inhibited atrial pace Ap-Ap(inhibited) is greater than the maximum pacing rate, e.g., about 110 bpm. If the atrial pacing rate exceeds the maximum atrial pacing rate, the CTT is terminated. If the atrial pacing rate is less than the maximum atrial pacing rate and fusion is not present, then the I/F and AIE counters are cleared 436 and the process loops to check the next cardiac event.

Figure 5 illustrates a process for performing an atrial pacing rate increase after a rate increase has been requested during rate initialization prior to an atrial CTT (see, FIGS. 1, 2A and 2B) or during the atrial CTT (see, FIGS. 3, 4A and 4B). If a rate increase has been requested, the device determines 510 whether or not the number of rate increases in the current test is greater than a maximum rate increases threshold. For example, the maximum rate increases threshold may be equal to about two such that if there have already been two rate request increases, then no additional rate increases are performed and the CTT is terminated. If, however, the number of rate increases is below 510 the maximum rate increases threshold, the device determines 520 if the current rate, e.g., the cardiac rate determined using Equation 1 above, is greater than the maximum cardiac rate. The maximum cardiac rate may be about 110 bpm, for example. If the current rate is greater than 520 the maximum cardiac rate, the test is terminated and may be retried at a later time. If the current rate is less than 520 the maximum cardiac rate, the pacing rate is increased 530. For example, the atrial pacing rate may be increased by about 10 bpm above the weighted average value determined by Equation 1. The atrial pacing rate increase is capped by the maximum pacing rate. For example, if the maximum pacing rate is 110 bpm, the pacing rate increment is 10 bpm, and the current pacing rate is 105 bpm, then a pacing rate increase would only increase the pacing rate to 110 bpm. The I/F, AIE counters are cleared 540 and the number of rate increases counter is incremented. In addition, the capture counter, non-capture counter and I/F counter may also be cleared. The CTT proceeds 550 at the increased atrial rate. The timing windows and respiration modulation index (RMI) used for the CTT may be initialized or reinitialized after the rate increase.

Modulation of the cardiac response signal due to respiration causes the slight changes in the signal that may obstruct accurate cardiac response determination. The CTT may determine a respiration modulation index (RMI) used to adjust thresholds and/or templates, etc., for cardiac response determination, e.g., capture, non-capture, fusion thresholds. After initializing the RMI, e.g., at the beginning of each test, the RMI is used throughout that test. RMI is a measure of respiration affect on atrial evoked response (AER) amplitude. During RMI determination, the device gathers AER peak amplitude data for a number of atrial paces and/or for a maximum number of cardiac cycles. In some cases the device gathers AER peak amplitude data for about 12 atrial paces and or about 25 cardiac cycles. RMI may be calculated by using Equation [2].

\[
RMI = \frac{\text{[(Avg AER amplitude of X beats)} - \text{(Min AER amplitude of X beats)]}}{\text{[2]}}
\]

(Avg AER amplitude of X beats)

Successful RMI values may be between about 0 to 0.3, for example. Some values may still be determined to be successful if they do not fall within this specified range and an upper threshold may be invoked. For example, using the acceptable values 0 to 0.3, RMI values greater than 0.3 but less than 0.4 may be acceptable, but RMI may be set to 0.3 for capture detection threshold calculations. RMI values greater than or equal to 0.4 in this example, may signify either that fusion is present, giving wide variation in evoked response peak amplitudes, or that the algorithm is pacing sub-threshold. In some cases, even when the upper threshold limit is not met and/or when the RMI initialization does not complete in the maximum number of cardiac cycles, the device may continue with threshold tests if other criteria are met. For example, the criteria may include that one or more of the following occurrences: 1) there are less than a number e.g. 2, small evoked responses (0.35 mV, for example); 2) there is a recent successful threshold test; 3) the
capture threshold is below a value such as 2.5 volts. Other criteria may also or alternatively be used. One or more of the criteria may be used to determine whether the device continues with threshold tests. The reasoning behind the use of the criteria is that RMI initialization may fail due to factors such as fusion or sub-threshold pacing. Fusion can be managed while sub-threshold pacing indicates a problem. Small evoked responses are often a sign of sub-threshold pacing, so too many sub-threshold paces are undesirable. Because capture thresholds generally do not change suddenly, e.g., from 2.5 to 4 V within the “recent” test time of about 21 hours, it is assumed that if the previous threshold was <= 2.5 V, the current RMI failure is caused by something other than sub-threshold pacing at 4.0 V. If these criteria are met, it may reasonably be concluded that fusion was the cause of the RMI failure and the test is allowed to continue with a default RMI value.

Referring now to FIG. 6 of the drawings, there is shown a cardiac rhythm management system that may be used to implement atrial capture threshold testing according to embodiments described herein. The system in FIG. 6 includes an implantable cardiac device (ICD) 600 electrically and physically coupled to a lead system 602. The header and/or housing of the ICD 600 may incorporate one or more electrodes 681a, 681b used to provide electrical stimulation energy to the heart and to sense cardiac electrical activity.

The lead system 602 is used to detect electric cardiac signals produced by the heart and to provide electrical energy to the heart under certain predetermined conditions to treat cardiac arrhythmias. The lead system 602 may include one or more electrodes used for pacing, sensing, and/or cardioversion/defibrillation. In the embodiment shown in FIG. 6, the lead system 602 includes an intracardiac right ventricular (RV) lead system, an intracardiac right atrial (RA) lead system, an intracardiac left ventricular (LV)/left atrial (LA) lead system. The lead system 602 of FIG. 6 illustrates one embodiment that may be used in connection with the capture threshold testing methodologies described herein. Other arrangements may additionally or alternatively be used.

The lead system 602 may include intracardiac leads implanted in a human body with portions of the intracardiac leads inserted into a heart. The intracardiac leads include various electrodes positionable within the heart for sensing electrical activity of the heart and for delivering electrical stimulation energy to the heart, for example, pacing pulses and/or defibrillation shocks to treat various arrhythmias of the heart.

The lead system may include one or more extracardiac leads having electrodes, e.g., epicardial electrodes, positioned at locations outside the heart for sensing and pacing one or more heart chambers.

The right ventricular lead system illustrated in Figure 6 includes an SVC-coil 641, an RV-coil 642, an RV-ring electrode 663, and an RV-tip electrode 653. The right ventricular lead system extends through the right atrium and into the right ventricle. In particular, the RV-tip electrode 653, RV-ring electrode 663, and RV-coil electrode 642 are positioned at appropriate locations within the right ventricle for sensing and delivering electrical stimulation pulses to the right ventricle. The SVC-coil 641 is positioned at an appropriate location within the right atrium chamber or a major vein leading to the right atrial chamber.

In one configuration, the RV-tip electrode 653 referenced to the can electrode 681b may be used to implement unipolar pacing and/or sensing in the right ventricle. Bipolar pacing and/or sensing in the right ventricle may be implemented using the RV-tip and RV-ring electrodes 653, 663. In yet another configuration, the RV-ring 663 electrode may optionally be omitted, and bipolar pacing and/or sensing may be accomplished using the RV-tip electrode 653 and the RV-coil 642, for example. The right ventricular lead system may be configured as an integrated bipolar pace/shock lead. The RV-coil 642 and the SVC-coil 641 can be used as defibrillation electrodes.

The left heart lead includes an LV distal electrode 655 and an LV proximal electrode 654 located at appropriate locations in or about the left ventricle for sensing signals of the left ventricle and/or delivering electrical stimulation to left ventricle. In the example of Figure 16, the left heart lead also includes optional left atrial electrodes 656, 657. The left heart lead may be guided into the right atrium via the superior vena cava. From the right atrium, the left heart lead may be deployed into the coronary sinus ostium and may be guided through the coronary sinus to a coronary vein. This vein is used as an access pathway for leads to reach the surfaces of the left atrium and/or left ventricle which are not directly accessible from the right side of the heart.

Unipolar pacing and/or sensing in the left ventricle may be implemented, for example, using the LV distal electrode 655 referenced to the can electrode 681b. The LV distal electrode 655 and the LV proximal electrode 654 may be used together as bipolar sense and/or pace electrodes for the left ventricle. The left heart lead and the right heart leads, in conjunction with the ICD 600, may be used to provide cardiac resynchronization therapy such that the ventricles and/or atria of the heart are paced substantially simultaneously, or in phased sequence, to provide enhanced cardiac pumping efficiency for patients suffering from congestive heart failure.

The right atrial lead includes a RA-tip electrode 652 and an RA-ring electrode 651 positioned at appropriate locations in the right atrium for sensing and pacing the right atrium. In one configuration, the RA-tip 652 referenced to the can electrode 681b, for example, may be used to provide unipolar pacing and/or sensing in the right atrium. In this configuration, RA-ring electrode 651 referenced to the can electrode 681b, for example, may be used to provide sensing of the RA evoked response. In another configuration, the RA-tip electrode 652 and the RA-ring electrode 651 may be used to effect bipolar pacing and/or sensing.
Figure 6 illustrates one embodiment of left atrial electrodes 656, 657. Unipolar pacing and/or sensing of the left atrium may be accomplished, for example, using the LA distal electrode 657 to the can 681b pacing vector. The LA proximal 656 and LA distal 657 electrodes may be used together to implement bipolar pacing and/or sensing of the left atrium.

Referring now to Figure 7, there is shown a block diagram of an embodiment of a cardiac system 700 suitable for implementing atrial capture threshold testing as described herein.

The cardiac system 700 includes a control processor 740 capable of controlling the delivery of pacing pulses or defibrillation shocks to the right ventricle, left ventricle, right atrium and/or left atrium. The pacing pulse generator 730 is configured to generate pacing pulses for treating bradyarrhythmia, for example, and/or for synchronizing the contractions of contralateral heart chambers using biaxial and/or biventricular pacing.

The control processor 740 may include an arrhythmia detector that operates to detect atrial or ventricular tachyarrhythmia or fibrillation. Under control of the control processor 740, the cardioversion/defibrillation pulse generator 735 is capable of generating high energy shocks to terminate the detected tachyarrhythmia episodes.

The pacing pulses and/or defibrillation shocks are delivered via multiple cardiac electrodes 705 electrically coupled to a heart and disposed at multiple locations within, on, or about the heart. One or more electrodes 705 may be disposed in, on, or about a heart chamber or at multiple sites of the heart chamber. The electrodes 705 are coupled to switch matrix 725 circuitry that is used to selectively couple the electrodes 705 to the sense circuitry 710 and the therapy pulse generators 730, 735.

The cardiac system 700 includes a pacing response classification (PRC) processor 715. In some embodiments, the PRC processor 715 is configured to discriminate between capture and non-capture. In some embodiments, the PRC processor is configured to discriminate between capture, noncapture and fusion. Pacing response classification is implemented by the PRC processor 715 for capture threshold testing and/or capture verification during therapeutic pacing. The PRC processor 715 is configured to determine various thresholds and intervals useful in the analysis of signals to determine the pacing response. For example, the PRC processor 715 may determine one or more of a pacing threshold interval (PTI), a pacing artifact threshold (PAT), and/or a capture detection threshold (CDT). Discrimination between capture, noncapture, and fusion is performed by the PRC processor 715 based on comparison of a cardiac signal sensed following a pacing impulse to one or more of the intervals or thresholds.

The control processor 740 includes a capture threshold module 743 that controls the operation of the cardiac system during capture threshold testing. The control processor 740 may include an atrial refractory period timer 741 for timing atrial refractory periods (ARP) and/or post ventricular atrial refractory periods (PVARP) following atrial and/or ventricular paced cycles and/or sensed cycles. The control processor 740 may optionally include a retrograde management module 742 configured to control pacing during retrograde management pacing cycles. The control processor 740 may optionally include pacemaker mediated tachycardia (PMT) management module 744 configured to control pacing during PMT management pacing cycles. The control processor 740 may also contain a rate management module 771 and/or a respiration modulation index module 772.

The capture threshold module 743 controls the delivery of paces by the pacing therapy pulse generator 730 during therapeutic pacing and during capture threshold testing. To determine the capture threshold, the capture threshold module 743 may control the delivery of a sequence of pacing pulses that incrementally step down or step up the pacing energy until a capture threshold is determined. Prior to beginning the capture threshold test, the capture threshold module 743 may control pacing during an initialization procedure. During the initialization procedure, the PRC processor 715 operates to determine thresholds and intervals described herein that are useful in cardiac pacing response classification. The thresholds and intervals determined in the initialization procedure are then used to determine the pacing responses to the threshold test paces. Prior to beginning the capture threshold test, the rate management module 771 may perform processes to initialize the cardiac rate for the CTT. The RMI module 772 may determine the RMI used during the CTT.

The CRM system 700 is typically powered by an electrochemical battery (not shown). A memory 745 stores data and program commands used to implement the CTT approaches described herein along with other features. Data and program commands may be transferred between the CRM system 700 and a patient-external device 755 via telemetry-based communications circuitry 750.

Figure 7 shows a CRM system 700 divided into functional blocks. It is understood by those skilled in the art that there exist many possible configurations in which these functional blocks can be arranged. The example depicted in Figure 7 is one possible functional arrangement. Other arrangements are also possible. For example, more, fewer or different functional blocks may be used to describe a cardiac system suitable for implementing the processes described herein. In addition, although the CRM system 700 depicted in Figure 7 contemplates the use of a programmable microprocessor-based logic circuit, other circuit implementations may be utilized.

Figure 8 is a flowchart illustrating a method for classifying the cardiac response to pacing a heart chamber, such as an atrial heart chamber, that may be implemented by a CRM device in accordance with embodiments described herein. The time between a delivered atrial pace and the evoked response signal peak is substantially consistent. A peak timing interval (PTI) may be established for examining the cardiac signal to determine the pacing response. The
A method in accordance with one embodiment involves discriminating between capture, noncapture, and fusion based on comparison of a sensed cardiac signal peak to a capture detection threshold (CDT), a pacing artifact threshold (PAT), and a peak timing interval (PTI). The PAT is determined 810 based on peak values of atrial signals of one or more noncaptured cardiac cycles, e.g., about 2 to about 4 cardiac cycles. The signals used to determine the PAT may be sensed following sub-capture threshold paces following a capture threshold test, for example. The sensed atrial signals associated with noncapture are pacing artifact signals that have a morphology exhibiting a pacing artifact without the evoked response morphology produced by capture. In various implementations, the PAT may be based on a combination of the peak values of the signals associated with noncapture. For example, the PAT may be based on the peak magnitude of a most recent cardiac signal associated with capture, the largest one or more peak magnitudes of the signals associated with noncapture, a mean value of the magnitudes of the signals associated with noncapture, or a weighted average of the magnitudes of the signals associated with capture, or other combination of the peak magnitudes of the signals associated with noncapture. The PAT may include an offset to take into account the variability of the peak magnitudes of the signals associated with noncapture. In one example, the PAT is set to a percentage, such as about 150%, of the peak magnitude of a most recent signal associated with noncapture.

A capture detection threshold (CDT) is determined 820 based on peak values of one or more evoked response signals, e.g., about 5 to about 10 signals, detected during one or more captured cardiac cycles. The signals used to determine the CDT follow supra capture threshold paces. The signals associated with capture exhibit a morphology that includes an evoked response signal having a superimposed pacing artifact signal. Similarly to the PAT determination described above, the CDT may be based on or a combination of the peak values of the signals associated with capture. The CDT may be based on a most recent peak magnitude of a signal associated with capture, the largest one or more peak magnitudes of the signals associated with capture, a median value of the peak magnitudes of the signals associated with capture, a mean value of the peak magnitudes of the signals associated with capture, or a weighted average of the peak magnitudes of the signals associated with capture, or other combination of the peak magnitudes of the signals associated with capture. The CDT may include an offset to take into account the variability of the peak magnitudes of the signals associated with capture. The use of a weighted average for the CDT provides such an offset, for example. In one embodiment, the CDT is set to a percentage of an average, e.g., about 70% of evoked response peak magnitudes.

A peak time interval (PTI) associated with an expected timing of the evoked response signal peak is used in conjunction with the PAT and the CDT. Discrimination between capture, noncapture, and fusion is based on comparison of the magnitude of the cardiac signal peak relative to the PAT and CDT and comparison of the timing of the cardiac signal peak relative to the PTI.

The PTI is determined based on the timing of peak values of one or more evoked response signals detected during one or more captured cardiac cycles. The signals used to determine the PTI follow supra capture threshold paces. The PTI may be determined based on the variability of the peak timing of the signals associated with capture, for example. A typical value of the PTI is about 9 ms, for example. The PTI may be based on a median value of the peak timings of the signals associated with capture, a mean value of the peak timings of the signals associated with capture, or a weighted average of the peak timings of the signals associated with capture, or other combination of the peak timings of the signals associated with capture. The PTI may include predetermined interval offsets on either side of a most recent, average, mean, or median timing value, for example, where the interval offsets take into account the variability of the peak timing of the signals associated with capture.

A cardiac signal following a pacing pulse of a cardiac cycle subsequent to the noncaptured cardiac cycles and the captured cardiac cycles is sensed 830. A peak value of the sensed cardiac signal falling within the PTI is compared 840 to the PAT and to the CDT. The device discriminates 850 between capture, noncapture, and fusion based on the comparison. If the signal peak is less than the PAT, then the pacing response is determined to be noncapture. If the signal peak is greater than the CDT, then the pacing response is determined to be capture. If the signal peak falls between the PAT and the CDT, then the pacing response may be noncapture or may be fusion.

Figure 9A is a graph illustrating the morphology of a captured response signal 910 sensed following an atrial pace (Ap). The peak 911 of the cardiac signal 910 depicted in Figure 9A has a magnitude (i.e., absolute value) larger than the PAT 930 and the CDT 940.

Figure 9B is a diagram illustrating regions used in pacing response discrimination in accordance with one embodiment. Figure 9B shows the PAT 930, the CDT 940, and the PTI 950 which define regions 960, 970, and 980 respectively associated with noncapture (NC), both noncapture and fusion, and capture. If the peak of a cardiac signal following pacing falls within a particular region 960, 970, 980, then the cardiac pacing response is classified as likely to be the type of response or responses associated with the region 960, 970, 980.

In one implementation, a counter for a particular type of response is incremented each time a peak falls within a region associated with the particular type of response. The counter increments may be integer or fractional increments. The counter increments may be based on the likelihood that a particular type of pacing response has occurred. For
example, region 970 is associated with both noncapture and fusion. However, it may be more likely that a peak falling in region 970 is fusion rather than noncapture. If a peak falls within region 970, the fusion counter (IF counter) may be incremented by 1 and the noncapture counter may be incremented by ½. In some scenarios, confirmation that a particular pacing response has been occurring may require several cardiac cycles. For example, confirmation of the particular type of pacing response may occur if a counter for the particular type of pacing response reaches a predetermined value.

Figure 10 is a flowchart illustrating step down capture threshold testing with pacing response classification based on the regions depicted in Figure 9B. The approaches described herein may advantageously be used in connection with capture threshold testing. Prior to beginning the step down test, the CDT and/or PTI are initialized 1005 based on the peak magnitudes of signals sensed following delivery of a series of supra capture threshold paces.

In one embodiment, the PAT is initialized to a predetermined value, such as about 0.3 mV prior to the capture threshold test. The CDT and PTI are initialized based on measured values of the peak magnitude and peak timing of captured signals. Initialization of the CDT and PTI prior to the test based on measured values provides patient specific values, enhancing the accuracy of capture testing. In addition, one or more of these parameters may be modified during and/or after the capture threshold test based on most recent peak timing and peak magnitude values to further enhance the test accuracy.

The pacing energy and the pacing rate are initialized 1010 for the test. A pace is delivered 1015 and the cardiac signal following the pace is sensed 1015. The peak magnitude (PM) of the cardiac signal is determined 1020. If the peak magnitude is less than or equal to 1025 the PAT, then the pace did not capture the chamber and the noncapture counter is incremented 1030. If the peak timing is within the PTI and the peak magnitude is greater than the PAT but is less than or equal to the CDT 1035, then the pacing response may be noncapture or may be fusion. Both the noncapture counter and the fusion counter are incremented 1040. If the peak timing is within the PTI and the peak magnitude is greater than the CDT, then the pacing response is 1045 capture and the capture counter is incremented 1050. Otherwise, the response is determined 1046 to be fusion.

The amounts that the counters for each type of response are incremented may be integer or fractional amounts. In some implementations, the amount that a particular counter is incremented is associated with the likelihood that the type of pacing response occurred. For example, if the peak magnitude falls between the PAT and the CDT, fusion is more likely than noncapture. In this scenario, the fusion counter may be incremented by 1 and the noncapture counter incremented by ½.

If the noncapture counter reaches 1055, 1056 a predetermined value, e.g., about 2, for paces having the same energy, then loss of capture is confirmed and the capture threshold is determined 1060. If the fusion counter reaches 1065 a predetermined value, e.g., about 5 intrinsic beats or fusion beats, and at a least a minimum number of atrial intrinsic beats have occurred, e.g., about 2, then the pacing rate is increased 1070 to decrease the occurrence of intrinsic/fusion beats. If the capture counter reaches 1075 a predetermined value, e.g., about 3 for paces having the same energy, then the pacing energy is stepped down 1080 and the test continues until the capture threshold is determined 1060.

In some implementations, the PAT, CDT, and PTI may be initialized before the test and/or one or more of these parameters may be modified during the test, such as during every cardiac cycle, and/or may be modified after the test. The PAT may be re-initialized in the case of certain failures.

In one example, the peak timing and/or peak magnitude may be determined for the cardiac signal of each beat. The peak timing and/or peak magnitude may be combined with peak timings and magnitudes of one or more previous beats to dynamically modify the PTI and CDT during the test. Modifying the PTI and/or CDT during the test may be used to adapt to changing patient conditions, providing more accurate values for these parameters. The PAT may be modified after the test based on one or more noncaptured signals, detected after the capture threshold is determined. Modifying the PAT based on a particular patient’s pacing artifact morphology allows for adaptation to changing patient conditions over time and provides more accurate pacing response classification.

Figure 11 is a diagram illustrating regions used in pacing response discrimination in accordance with another embodiment. Fusion beats usually exhibit large variations in peak timing of the cardiac signal when compared to captured beats. Regions corresponding to time intervals before and/or after the PTI may be used for fusion discrimination. Figure 11 shows the PAT 1130, the CDT 1140, and the PTI 1150 which define regions 1161-1163 associated with noncapture, region 1170 associated with noncapture and fusion, region 1180 associated with capture, and regions 1191-1194 associated with fusion. If the peak of a cardiac signal following pacing falls within a particular region, then the cardiac pacing response is likely to be the type of response associated with the region.

As previously described, a counter for a particular type of response may be incremented each time a peak falls within a region associated with the particular type of response. The increments may be integer or fractional increments. The counter increments may be based on the likelihood that a particular type of pacing response has occurred. For example, region 1170 is associated with both noncapture and fusion. However, it may be more likely that a peak falling in region 1170 is fusion rather than noncapture. If a peak falls within region 1170, the fusion counter may be incremented by 1 and the noncapture may be incremented by ½. In some scenarios, confirmation that a particular pacing response
Figures 12A-12B illustrate a flowchart illustrating step down capture threshold testing with pacing response classification based on the regions depicted in Figure 11. Prior to beginning the step down test, the PAT, CDT, and PTI are initialized to 1205. The PAT is initialized to a predetermined value. The CDT is initialized based on peak magnitudes, \( P_{m} \), of signals sensed following delivery of supra capture threshold paces. PTI is initialized based on the peak timing, \( P_{t} \), of signals sensed following delivery of supra capture threshold paces. The pacing energy and the pacing rate are initialized 1210 for the test.

A pace is delivered 1215 and the cardiac signal following the pace is sensed 1215. The peak magnitude, \( P_{m} \), of the cardiac signal is determined 1220. If the peak magnitude is less than or equal to 1225 the PAT, then the pace did not capture the chamber and the noncapture counter is incremented 1230. If the peak magnitude is greater than the PAT and the timing of the peak does not fall 1235 within the PTI, then the pacing response is likely to be fusion and the fusion counter is incremented 1240.

If the timing of the peak falls within the PTI and the peak magnitude is greater than the PAT and less than or equal to 1245 the CDT, then the pacing response may be fusion or noncapture. The fusion counter and the noncapture counter are incremented 1250. If the peak magnitude is greater than the CDT, then the pacing response is 1255 capture and the capture counter is incremented 1260.

As previously described, the amounts that the counters for each type of response are incremented may be integer or fractional amounts. In some implementations, the amount that a particular counter is incremented is associated with the likelihood that the type of pacing response occurred. For example, if the peak magnitude falls between the PAT and the CDT, fusion is more likely than noncapture. In this scenario, the fusion counter may be incremented by 1 and the noncapture counter incremented by \( \frac{1}{2} \).

If the noncapture counter reaches 1270, 1271 a predetermined value, e.g., about 2, for paces having the same energy, then loss of capture is confirmed and the capture threshold is determined 1275. If the fusion counter reaches 1280 a predetermined value, e.g., about 5 intrinsic or fusion beats, with a minimum number of intrinsic beats, e.g., about 2, then the pacing rate is increased 1285 to avoid the occurrence of intrinsic/fusion beats. If the capture counter reaches 1290 a predetermined value, e.g., about 3 for paces having the same energy, then the pacing energy is stepped down 1295 and the test continues until the capture threshold is determined 1275. Following the capture threshold test, the PAT may be updated based on the peak magnitude of one or more noncaptured signals.

During pacing, if noncapture occurs, retrograde conduction from an intrinsic or paced ventricular depolarization may cause a false noncapture detection on the next pacing cycle. Retrograde conduction during capture threshold testing, for example, may lead to erroneous capture threshold determination. Retrograde conduction may also cause undesirable fast pacing, denoted pacemaker mediated tachyarrhythmia (PMT). Some embodiments described herein include methods and systems that provide for management of retrograde conduction and PMT.

The flowchart of Figure 13 illustrates an approach implementable in a CRM system for retrograde conduction management and PMT management in accordance with embodiments described herein. An atrial pace and a ventricular pace are delivered 1310 during a cardiac cycle. A post ventricular atrial refractory period (PVARP) is timed 1320 following the ventricular pace. The CRM system determines 1330 if the atrial pace captured the atrium. In some embodiments, capture may be detected based on comparison of peak magnitude and timing of the cardiac signal following pacing to the CDT, PAT, and PTI as described above. In other embodiments, capture may be determined using other capture detection methods known in the art.

If capture occurs, the depolarization associated with capture causes tissue refractoriness, making retrograde conduction unlikely. If noncapture occurs, the atrial tissue is not refractory after the pace and the ventricular depolarization may conduct retrogradely to the atrium. The system senses 1340 an atrial depolarization following the pacing cycle indicative of retrograde conduction. Retrograde management is initiated 1350 if the atrial pacing pulse did not capture and an atrial depolarization is sensed during the PVARP. PMT management is initiated 1360 if the atrial pacing pulse did not capture and an atrial depolarization is sensed after the PVARP.

The timing diagram of Figure 14 illustrates a scenario where noncapture is erroneously detected due to retrograde conduction. A noncaptured atrial pace 1410 and a ventricular pace 1430 are delivered during a first cardiac cycle. A PVARP 1420 is timed following the ventricular pace 1430. In this cycle, the atrial pace may be accurately detected as noncapture. However, confirmation of the loss of capture during a capture threshold test typically requires more than one noncaptured pace, such as several noncaptured paces detected consecutively or within a short period of time. If a noncapture event was caused by transient effects, such as noise, rather than by the decrease in the pacing energy, then loss of capture would not be confirmed because subsequent paces would be captured and the test would continue. However, a pattern of retrograde conduction may be initiated by the noncaptured pace, causing a single noncaptured pace to result in an erroneous loss of capture confirmation as described below.

Because the atrial pace 1410 did not produce capture, the depolarization caused by the ventricular pace causes retrograde conduction to the atrium. The retrograde conduction produces an atrial depolarization 1440 causing the atrial
tissue to become refractory. The atrial depolarization 1440 does not initiate a new pacing cycle because it occurs during PVARP 1420. The atrial pace 1411 for the next cycle is delivered during the tissue refractory period 1450. Because the atrial pace 1411 is delivered while the tissue is refractory, the pace 1411 is detected as noncapture. During a capture threshold test, the noncaptured atrial pace causes a false detection of noncapture because the noncapture is the result of tissue refractoriness following retrograde conduction rather than the change in the pacing energy level. Noncapture of the atrial pace 1411 during the second cardiac cycle again causes retrograde conduction, an atrial depolarization 1441, and tissue refractoriness. The pattern of false noncapture detection and retrograde conduction may continue resulting in a confirmation of loss of capture and an erroneous capture threshold measurement.

The timing diagram illustrated in Figure 15 illustrates retrograde management in accordance with embodiments described herein. The atrial pace 1510 of the first cardiac cycle is noncaptured. The ventricular pace 1520 of the first cardiac cycle causes retrograde conduction to the atrium. An atrial depolarization 1540 produced by the retrograde conduction causes the atrial tissue to become refractory during a tissue refractory period 1550. The atrial depolarization 1540 does not initiate a new pacing cycle because the atrial depolarization occurs during PVARP 1520. The CRM system senses the atrial depolarization 1540 that occurs during the PVARP 1520. The next scheduled atrial pace 1511 for the cycle following the retrograde conduction is delayed until after the tissue refractory period 1550 ends. Typically the period 1550 of tissue refractoriness lasts less than 300 ms after the depolarization 1540 is sensed, for example. Therefore, the next scheduled atrial pace 1511 in this example is delayed until about 300 ms following the atrial depolarization 1540.

The delayed pace 1511 is correctly classified as a captured pace. The third cardiac cycle includes an atrial pace 1512 and a ventricular pace 1532 that are delivered at the scheduled time.

Figures 14 and 15 above illustrate retrograde conduction when the retrograde atrial depolarization occurs during PVARP. In this scenario, the retrograde atrial depolarization does not initiate a new pacing cycle. Retrograde conduction producing atrial depolarizations that occur after PVARP has expired may result in PMT. PMT caused by retrograde conduction is illustrated in the timing diagram of Figure 16. The first cardiac cycle includes a noncaptured atrial pace 1610 and a captured ventricular pace 1630. PVARP 1620 is timed following the ventricular pace 1630, 1631 for each cycle. The noncaptured atrial pace 1610 in the first cycle allows the depolarization initiated by the captured ventricular pace 1630 of the first cycle to conduct retrogradely to the atrium. An atrial depolarization caused by the retrograde conduction causes a nonrefractory atrial sense. Because the atrial sense 1641 occurs after expiration of PVARP 1620 (i.e., is a nonrefractory sense), the CRM system initiates a pacing cycle in the second cardiac cycle which is abnormally fast. The pattern of fast ventricular paces and retrograde atrial depolarizations that occur after PVARP continues in the third and fourth cycles. The pacing cycles of Figure 16 illustrate PMT.

The timing diagram illustrated in Figure 17 illustrates PMT management in accordance with embodiments described herein. The first pacing cycle includes a noncaptured atrial pace 1710 and a captured ventricular pace 1730. The noncaptured atrial pace 1710 allows the depolarization caused by the ventricular pace to be retrogradely conducted to the atrium. The retrograde conduction occurs after PVARP for the cycle has expired. The nonrefractory atrial sense 1740 caused by the retrograde conduction is used by the CRM system to initiate a pacing cycle. The next ventricular pace 1731 is fast.

The CRM system initiates PMT management following the noncaptured atrial pace 1710 in the first cycle and the nonrefractory atrial sense 1740 initiating the second cycle. The PVARP 1721 for the pacing cycle following the noncaptured pace 1710, which is the second cycle illustrated in Figure 17, is extended to break the PMT pattern. The next atrial sense 1741 occurs in the extended PVARP 1721 and does not initiate a pacing cycle. The third cardiac cycle illustrated in Figure 17 is a normal cycle.

The flowchart of Figure 18 illustrates retrograde conduction management and PMT management in accordance with embodiments described herein. An atrial pace and a ventricular pace are delivered 1810 during a pacing cycle. An atrial refractory period is timed 1820 for the pacing cycle. A refractory or nonrefractory atrial depolarization is sensed 1830. If the atrial pace did not capture 1840 the atrium and the atrial depolarization was sensed 1850 after expiration of the refractory period, then PVARP is increased 1860 for one cardiac cycle. For example, the PVARP may be extended to about 500 ms. Extending the PVARP to 500 ms for one cardiac cycle breaks the PMT.

If the atrial pace did not capture 1840 the atrium and the atrial depolarization was sensed 1850 during the refractory period, the system checks to determine 1870 if the time between the atrial depolarization and the next scheduled atrial pace is greater than the tissue refractory period (TRP). If not, the time for the next scheduled pace is extended 1880 to avoid retrograde conduction in subsequent cardiac cycles. For example, the time for the next pace may be extended so that there is about 300 ms between the refractory atrial sense and the next pace.

It is understood that the components and functionality depicted in the figures and described herein can be implemented in hardware, software, or a combination of hardware and software.

The invention is set out in the following claims.
Claims

1. A method of setting a pacing rate for an atrial capture threshold test using a cardiac device, comprising:
   detecting cardiac cycles;
   monitoring (110, 320) cardiac events of a cardiac chamber that occur during the cardiac cycles;
   counting (130, 330) a number of atrial intrinsic beats in the cardiac events;
   counting a number of atrial fusion beats in the cardiac events;
   maintaining (360) the pacing rate for the capture threshold test if the number of both of atrial intrinsic beats and
   atrial fusion beats in the cardiac events is less than a threshold; and
   increasing (350) the pacing rate for the capture threshold test if the number of both of atrial intrinsic beats and
   atrial fusion beats in the cardiac events is greater than the threshold.

2. The method of claim 1, further comprising:
   determining if the pacing rate is greater than a maximum rate.

3. The method of claim 1, wherein monitoring the cardiac events further comprises monitoring the cardiac events that
   occur during the cardiac cycles until a predetermined number of cardiac events has occurred (250-260).

4. The method of claim 1, further comprising counting (330) a number of consecutive cardiac events that are atrial
   intrinsic beats or atrial fusion beats to determine an intrinsic/fusion beat count.

5. The method of claim 4, wherein the pacing rate is increased (432, 434) if the intrinsic/fusion beat count exceeds an
   intrinsic/fusion threshold and the number of atrial intrinsic beats in the intrinsic/fusion beat count is greater than a
   minimum threshold.

6. The method of claim 1, further comprising:
   maintaining the pacing rate if the intrinsic/fusion beat count is less than a predetermined value; and
   increasing (432, 434), the pacing rate if the intrinsic/fusion beat count is greater than an intrinsic/fusion threshold
   and the number of atrial intrinsic beats in the intrinsic/fusion beat count is greater than a minimum threshold.

7. A cardiac device (600), comprising:
   sensing circuitry (710) configured to detect cardiac signals that include indications of cardiac events;
   a control processor (740) configured to monitor the cardiac events that occur during cardiac cycles and to count
   a number of atrial intrinsic beats and atrial fusion beats in the cardiac events, the control processor including
   circuitry (771) configured to set a pacing rate for an atrial capture threshold test (CTT), wherein the control
   processor is configured to maintain the pacing rate for the capture threshold test if the number of both of atrial
   intrinsic beats and atrial fusion beats in the cardiac events is less than a threshold, and to increase the pacing
   rate for the capture threshold test if the number of both of atrial intrinsic beats and atrial fusion beats in the
   cardiac events is greater than the threshold; and
   pacing circuitry (730, 705) configured to deliver pacing during the capture threshold test using the pacing rate.

8. The device of claim 7, wherein the control processor is configured to determine if the pacing rate is greater than a
   maximum rate.

9. The device of claim 7, wherein the control processor is configured to monitor the cardiac events that occur during
   the cardiac cycles until a predetermined number of cardiac events have occurred.

10. The device of claim wherein the control processor is configured to count a number of consecutive cardiac events
    that are atrial intrinsic beats or atrial fusion beats to determine an intrinsic/fusion beat count.

11. The device of claim 10, wherein the control processor is configured to maintain the pacing rate if the intrinsic/fusion
    beat count is less than a predetermined value and to increase the pacing rate if the intrinsic/fusion beat count is
    greater than an intrinsic/fusion threshold and the number of atrial intrinsic beats in the intrinsic/fusion beat count is
    greater than a minimum threshold.
12. The device of claim 7, wherein the control processor is configured to detect cardiac cycles by detecting cardiac cycle end events.

13. The device of claim 7, wherein the control processor sets the pacing rate before executing the atrial capture threshold test.

**Patentansprüche**

1. Verfahren zum Setzen einer Schrittgaberate für eine Prüfung eines atrialen Erfassungsschwellenwerts unter Verwendung einer Herzvorrichtung, welches aufweist:

   Erfassen von Herzzyklen;
   Überwachen (110, 320) von Herzereignissen einer Herzkammer, die während der Herzzyklen auftreten;
   Zählen (130, 330) einer Anzahl von intrinsischen atrialen Schlägen in den Herzereignissen;
   Zählen einer Anzahl von atrialen Fusionsschlägen in den Herzereignissen;
   Aufrechterhalten (360) der Schrittgaberate für die Prüfung des Erfassungsschwellenwerts, wenn die Anzahl von sowohl den intrinsischen atrialen Schlägen als auch den atrialen Fusionsschlägen in den Herzereignissen geringer als ein Schwellenwert ist; und
   Erhöhen (350) der Schrittgaberate für die Prüfung des Erfassungsschwellenwerts, wenn die Anzahl sowohl der intrinsischen atrialen Schläge als auch der atrialen Fusionsschläge in den Herzereignissen größer als der Schwellenwert ist.

2. Verfahren nach Anspruch 1, welches weiterhin aufweist:

   Bestimmen, ob die Schrittgaberate größer als eine maximale Rate ist.

3. Verfahren nach Anspruch 1, bei dem das Überwachen der Herzereignisse weiterhin das Überwachen der Herzereignisse aufgetreten, die während der Herzzyklen auftreten, bis eine vorbestimmte Anzahl von Herzereignissen aufgetreten ist (250 - 260).

4. Verfahren nach Anspruch 1, weiterhin aufweisend das Zählen (330) einer Anzahl von aufeinanderfolgenden Herzereignissen, die intrinsische atriale Schläge oder atriale Fusionsschläge sind, um eine Anzahl von intrinsischen/Fusions-Schlägen zu bestimmen.

5. Verfahren nach Anspruch 4, bei dem die Schrittgaberate erhöht wird (432, 434), wenn die Anzahl von intrinsischen/Fusions-Schlägen einen intrinsischen/Fusions-Schwellenwert überschreitet und die Anzahl von intrinsischen atrialen Schlägen in der Anzahl von intrinsischen/Fusions-Schlägen größer als ein minimaler Schwellenwert ist.

6. Verfahren nach Anspruch 4, weiterhin aufweisend:

   Aufrechterhalten der Schrittgaberate, wenn die Anzahl von intrinsischen/Fusions-Schlägen geringer als ein vorbestimmter Wert ist; und
   Erhöhen (432, 434) der Schrittgaberate, wenn die Anzahl der intrinsischen/Fusions-Schläge größer als ein intrinsischer/Fusions-Schwellenwert ist und die Anzahl von intrinsischen atrialen Schlägen in der Anzahl von intrinsischen/Fusions-Schlägen größer als ein minimaler Schwellenwert ist.

7. Herzvorrichtung (600), welche aufweist:

   eine Erfassungsschaltung (710), die konfiguriert ist, Herzsignale zu erfassen, die Anzeigen von Herzereignissen enthalten;
   einen Steuerprozessor (740), der konfiguriert ist zum Überwachen der Herzereignisse, die während Herzzyklen auftreten, und zum Zählen einer Anzahl von intrinsischen atrialen Schlägen und atrialen Fusionsschlägen in den Herzereignissen, wobei der Steuerprozessor eine Schaltung (771) enthält, die konfiguriert ist zum Setzen einer Schrittgaberate für eine Prüfung eines atrialen Erfassungsschwellenwerts (CTT), wobei der Steuerprozessor konfiguriert ist, die Schrittgaberate für die Prüfung des Erfassungsschwellenwerts aufrechtzuerhalten, wenn die Anzahl sowohl der intrinsischen atrialen Schläge als auch der atrialen Fusionsschläge in den Herzereignissen geringer als ein Schwellenwert ist, und zum Erhöhen der Schrittgaberate für die Prüfung des Er-
fassungsschwellenwerts, wenn die Anzahl sowohl der intrinsischen atrialen Schläge als auch der atrialen Fusionsschläge in den Herzereignissen größer als der Schwellenwert ist; und

eine Schrittgabeschaltung (730, 705), die konfiguriert ist zum Liefern einer Schrittgabe während der Prüfung des Erfassungsschwellenwerts unter Verwendung der Schrittgaberate.

8. Vorrichtung nach Anspruch 7, bei der der Steuerprozessor konfiguriert ist zum Bestimmen, ob die Schrittgaberate größer als eine maximale Rate ist.

9. Vorrichtung nach Anspruch 7, bei der der Steuerprozessor konfiguriert ist, die Herzereignisse, die während der Herzzyklen auftreten, zu überwachen, bis eine vorbestimmte Anzahl von Herzereignissen aufgetreten ist.

10. Vorrichtung nach Anspruch 7, bei der der Steuerprozessor konfiguriert ist, eine Anzahl von aufeinanderfolgenden Herzereignissen zu zählen, die intrinsische atriale Schläge oder atriale Fusionsschläge sind, um eine Anzahl von intrinsischen/Fusions-Schlägen zu bestimmen.

11. Vorrichtung nach Anspruch 10, bei der der Steuerprozessor konfiguriert ist zum Aufrechterhalten der Schrittgaberate, wenn die Anzahl der intrinsischen/Fusions-Schläge kleiner als ein vorbestimmter Wert ist, und zum Erhöhen der Schrittgaberate, wenn die Anzahl der intrinsischen/Fusions-Schläge größer als ein intrinsischer/Fusions-Schwellenwert ist und die Anzahl von intrinsischen atrialen Schlägen in der Anzahl von intrinsischen/Fusions-Schlägen größer als ein minimaler Schwellenwert ist.

12. Vorrichtung nach Anspruch 7, bei der der Steuerprozessor konfiguriert ist zum Erfassen von Herzzyklen durch Erfassen von Herzzyklus-Endereignissen.

13. Vorrichtung nach Anspruch 7, bei der der Steuerprozessor die Schrittgaberate setzt, bevor die Prüfung des atrialen Erfassungsschwellenwerts durchgeführt wird.

Revendications

1. Procédé d’instauration d’un rythme de stimulation cardiaque pour un test de seuil de capture d’oreillette en utilisant un dispositif cardiaque, comprenant :

la détection de cycles cardiaques ;
la surveillance (110, 320) d’événements cardiaques d’une chambre cardiaque qui surviennent pendant les cycles cardiaques ;
le comptage (130, 330) d’un nombre de battements intrinsèques d’oreillette dans les événements cardiaques ;
le comptage d’un nombre de battements de fusion d’oreillette dans les événements cardiaques ;
le maintien (360) du rythme de stimulation cardiaque pour le test de seuil de capture si le nombre à la fois de battements intrinsèques d’oreillette et de battements de fusion d’oreillette dans les événements cardiaques est inférieur à un seuil ; et
l’augmentation (350) du rythme de stimulation cardiaque pour le test de seuil de capture si le nombre à la fois de battements intrinsèques d’oreillette et de battements de fusion d’oreillette dans les événements cardiaques est supérieur au seuil.

2. Procédé selon la revendication 1, comprenant en outre :

la détermination de si le rythme de stimulation cardiaque est supérieur à un rythme maximum.

3. Procédé selon la revendication 1, dans lequel la surveillance des événements cardiaques comprend en outre la surveillance des événements cardiaques qui surviennent pendant les cycles cardiaques jusqu’à ce qu’un nombre prédéterminé d’événements cardiaques soient survenus (250-260).

4. Procédé selon la revendication 1, comprenant en outre le comptage (330) d’un nombre d’événements cardiaques consécutifs qui sont des battements intrinsèques d’oreillette ou des battements de fusion d’oreillette afin de déterminer un comptage de battements intrinsèques/de fusion.

5. Procédé selon la revendication 4, dans lequel le rythme de stimulation cardiaque est augmenté (432, 434) si le
comptage de battements intrinsèques/de fusion excède un seuil intrinsèque/de fusion et si le nombre de battements intrinsèques d'oreillette dans le comptage de battements intrinsèques/de fusion est supérieur à un seuil minimum.

6. Procédé selon la revendication 4, comprenant en outre :

   le maintien du rythme de stimulation cardiaque si le comptage de battements intrinsèques/de fusion est inférieur à une valeur prédéterminée ; et

   l'augmentation (432, 434) du rythme de stimulation cardiaque si le comptage de battements intrinsèques/de fusion est supérieur à un seuil intrinsèque/de fusion et si le nombre de battements intrinsèques d'oreillette dans le comptage de battements intrinsèques/de fusion est supérieur à un seuil minimum.

7. Dispositif cardiaque (600), comprenant :

   un circuit de détection (710) configuré pour détecter des signaux cardiaques qui incluent des indications d'événements cardiaques ;

   un processeur de commande (740) configuré pour surveiller les événements cardiaques qui surviennent pendant des cycles cardiaques et pour compter un nombre de battements intrinsèques d'oreillette et de battements de fusion d'oreillette dans les événements cardiaques, le processeur de commande incluant un circuit (771) configuré pour instaurer un rythme de stimulation cardiaque pour un test de seuil de capture (CTT) d'oreillette, dans lequel le processeur de commande est configuré pour maintenir le rythme de stimulation pour le test de seuil de capture si le nombre à la fois de battements intrinsèques d'oreillette et de battements de fusion d'oreillette dans les événements cardiaques est inférieur à un seuil, et pour augmenter le rythme de stimulation cardiaque pour le test de seuil de capture si le nombre à la fois de battements intrinsèques d'oreillette et de battements de fusion d'oreillette dans les événements cardiaques est supérieur au seuil ; et

   un circuit de stimulation cardiaque (730, 705) configuré pour délivrer une stimulation cardiaque pendant le test de seuil de capture en utilisant le rythme de stimulation cardiaque.

8. Dispositif selon la revendication 7, dans lequel le processeur de commande est configuré pour déterminer si le rythme de stimulation cardiaque est supérieur à un rythme maximum.

9. Dispositif selon la revendication 7, dans lequel le processeur de commande est configuré pour surveiller les événements cardiaques qui surviennent pendant les cycles cardiaques jusqu'à ce qu'un nombre prédéterminé d'événements cardiaques soient survenus.

10. Dispositif selon la revendication 7, dans lequel le processeur de commande est configuré pour compter un nombre d'événements cardiaques consécutifs qui sont des battements intrinsèques d'oreillette ou des battements de fusion d'oreillette afin de déterminer un comptage de battements intrinsèques/de fusion.

11. Dispositif selon la revendication 10, dans lequel le processeur de commande est configuré pour maintenir le rythme de stimulation cardiaque si le comptage de battements intrinsèques/de fusion est inférieur à une valeur prédéterminée et pour augmenter le rythme de stimulation cardiaque si le comptage de battements intrinsèques/de fusion est supérieur à un seuil intrinsèque/de fusion et si le nombre de battements intrinsèques d'oreillette dans le comptage de battements intrinsèques/de fusion est supérieur à un seuil minimum.

12. Dispositif selon la revendication 7, dans lequel le processeur de commande instaure le rythme de stimulation cardiaque avant l'exécution du test de seuil de capture d'oreillette.

13. Dispositif selon la revendication 7, dans lequel le processeur de commande instaure le rythme de stimulation cardiaque en détectant des cycles cardiaques en détectant des événements de fin de cycle cardiaque.
FIG. 1
FIG. 2A
FIG. 2B
300

Monitor atrial events including intrinsic atrial beats, paced atrial beats and atrial fusion beats

320

330

Count the number of consecutive atrial events that are intrinsic atrial beats or atrial fusion beats

340

360

Number of consecutive intrinsic or fusion beats with a minimum number of senses greater than a threshold?

no

Stay at current pacing rate

yes

350

Increase pacing rate

FIG. 3
Intrinsic/fusion beat management

Cardiac cycle end event?

yes

Update weighted cardiac rate (or cycle time)

Weighted rate > maximum rate?

no

Clear CHR counter

yes

Increment consecutive high rate (CHR) counter and total high rate (THR) counter

CHR > maxCHR?

yes

Terminate/retry test

no

THR > maxTHR?

yes

no

B

FIG. 4A
**FIG. 4B**
FIG. 5
Determine a pacing artifact threshold based on peak values of one or more pacing artifact signals

Determine a capture detection threshold based on peak values of one or more evoked response signals

Sense a cardiac signal following pacing for a subsequent cardiac cycle

Compare the peak value of the cardiac signal to the pacing artifact threshold and the capture detection threshold

Discriminate between capture, noncapture and fusion based on the comparison

FIG. 8
FIG. 9B
FIG. 10

1005 Initialize PAT, PTI, and/or CDT

1010 Initialize pacing energy and pacing rate

1015 Deliver pace, sense cardiac signal

1020 Determine peak magnitude ($P_m$) and peak timing ($P_t$)

1025 $P_m \leq$ PAT?  
   yes 1030 Increment NC counter  
   no  

1035 $P_t$ within PTI?  
   yes 1040 Increment NC counter and fusion counter
   no 1045 $P_m >$ CDT?  
      yes 1050 Increment capture counter
      no 1046 Fusion

1055 2 NC at same energy?  
   yes 1060 Capture threshold determined
   no  

1056 2 NC at same energy?  
   yes  
   no 1065 5 intrinsic/fusion beats?  
      yes 1070 Increase pacing rate  
      no  

1060

1070
FIG. 11
Initialize PAT, CDT, and PTI

Initialize pacing energy and pacing rate

Deliver pace, sense cardiac signal

Determine peak magnitude ($P_m$)

$P_m \leq \text{PAT}$?

yes

Increment NC counter

no

2 NC at same energy?

no

yes

Capture threshold determined
Deliver an atrial pacing pulse and a ventricular pacing pulse during a pacing cycle

Time PVARP following the ventricular pace

Determine if the atrial pace captures the atrium

Sense an atrial depolarization following the cardiac cycle

Initiate retrograde management if the atrial pacing pulse did not capture and the atrial depolarization occurred during PVARP

Initiate PMT management if the atrial pacing pulse did not capture and the atrial depolarization did not occur during PVARP

FIG. 13
FIG. 14
FIG. 15
Deliver atrial pace and ventricular pace during a pacing cycle

Time an atrial refractory period for the pacing cycle

Sense a refractory or nonrefractory atrial depolarization

Did the atrial pace capture the chamber?

Was the depolarization refractory?

Is time between depolarization and next pace > TRP?

1810

1820

1830

1840

1850

1860

1870

1880

yes

no

yes

no

Increase PVARP for one cycle

FIG. 18

Extend the next scheduled pace
REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader’s convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

• US 20080119902 A1 [0002]
• EP 1118351 A2 [0003]
• US 20030208241 A [0004]